Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.40 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 6/20 | 0.38 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1540153 | 0.99 | HCAR2 (0.41) | HCAR2SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL1540152 | 0.87 | CCNE2 (0.39) | SMN1; SMN2ALDH1A1KDM4EHPGDCCNE1 | |
| SCHEMBL1539914 | 0.83 | CDC7 (0.45) | SMN1; SMN2ALDH1A1KDM4EHPGDCCNE1 | |
| SCHEMBL951493 | 0.79 | CA1 (0.46) | HCAR2SMN1; SMN2ALDH1A1KDM4EHPGD | |
| Hydrochloric Acid SCHEMBL1984391 | 0.78 | CA1 (0.45) | HCAR2SMN1; SMN2ALDH1A1KDM4EHPGD | |
| Hydrochloric Acid SCHEMBL5663258 | 0.75 | L3MBTL1 (0.40) | HCAR2SMN1; SMN2ALDH1A1FFAR2RAB9A | |
| SCHEMBL17029212 | 0.74 | MAPK14 (0.63) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4299723 | 0.73 | BCHE (0.43) | HCAR2SMN1; SMN2ALDH1A1KDM4EHPGD | |
| SCHEMBL186141 | 0.72 | HCAR2 (0.53) | HCAR2SMN1; SMN2CCNE1CDK2CCNE2 | |
| SCHEMBL1540081 | 0.71 | LCK (0.43) | SMN1; SMN2ALDH1A1HPGDRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1610780-B2 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2022-11-23 | — | — | EP | disclosed |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-11 | — | — | US | disclosed |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-18 | — | — | US | disclosed |
| EP-3222619-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Holdings Ireland (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-20160264537-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-09-15 | — | — | US | disclosed |
| US-9382219-B2 | Cyclic protein tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150259337-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF DASATINIB | CERBIOS-PHARMA SA (CH) | 2015-09-17 | — | — | US | disclosed |
| EP-2918584-A1 | Process and intermediates for the preparation of dasatinib | Cerbios-Pharma S.A. (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-9115124-B1 | Process and intermediates for the preparation of dasatinib | CERBIOS-PHARMA SA (CH) | 2015-08-25 | — | — | US | disclosed |
| US-20150158830-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-11 | — | — | US | disclosed |
| US-20050261305-A1 | Reacting 4-(2-hydroxyethyl)piperazine and 2-((2-methyl,6-chloro-pyrimidin-4-yl)-amino),5-(2-chloro,6-methyl-phenyl)thiazole to obtain 2-((2-hydroxyethyl)piperazin-4-yl)-(2-methylpyrimidin-6,4-ylene)amino-),5-(2-chloro,6-methyl-phenyl)thiazole; antiarthritic,-tumor, -carcinogentic agents; immunology | DAS JAGABANDHU | 2005-11-24 | — | — | US | disclosed |
| EP-1169038-A4 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004085388-A2 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040077875-A1 | (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer | DAS JAGABANDHU (US) | 2004-04-22 | — | — | US | disclosed |
| US-20040073026-A1 | Autoimmune diseases; anticancer agents | DAS JAGABANDHU (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040054186-A1 | Cyclic protein tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | disclosed |
| US-20040024208-A1 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | DAS JAGABANDHU (US) | 2004-02-05 | — | — | US | disclosed |
| US-6596746-B1 | protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders; dasatinib | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | disclosed |
| EP-1169038-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000062778-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158830-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | HCAR2 3940/4885SMN1; SMN2 3827/4885ALDH1A1 4758/4885 |
| US-20040073026-A1 | Autoimmune diseases; anticancer agents | LCK, SSB, JAK1 | HCAR2 3108/4885SMN1; SMN2 3879/4885ALDH1A1 4643/4885 |
| US-20180016247-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | HCAR2 3940/4885SMN1; SMN2 3827/4885ALDH1A1 4758/4885 |
| US-20150259337-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF DASATINIB | ABL1, SRC, ABL2 | HCAR2 4689/4885SMN1; SMN2 2110/4885ALDH1A1 1654/4885 |
| US-20040077875-A1 | (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer | JAK1, LCK, MERTK | HCAR2 917/4885SMN1; SMN2 3468/4885ALDH1A1 3806/4885 |
| US-20190210986-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | HCAR2 3940/4885SMN1; SMN2 3827/4885ALDH1A1 4758/4885 |
| US-20040024208-A1 | Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology | TPMT, JAK1, CHUK | HCAR2 409/4885SMN1; SMN2 4666/4885ALDH1A1 2961/4885 |
| US-20160264537-A1 | CYCLIC PROTEIN TYROSINE KINASE INHIBITORS | LCK, ABL1, BTK | HCAR2 3940/4885SMN1; SMN2 3827/4885ALDH1A1 4758/4885 |
| US-20050261305-A1 | Reacting 4-(2-hydroxyethyl)piperazine and 2-((2-methyl,6-chloro-pyrimidin-4-yl)-amino),5-(2-chloro,6-methyl-phenyl)thiazole to obtain 2-((2-hydroxyethyl)piperazin-4-yl)-(2-methylpyrimidin-6,4-ylene)amino-),5-(2-chloro,6-methyl-phenyl)thiazole; antiarthritic,-tumor, -carcinogentic agents; immunology | JAK2, JAK1, TYK2 | HCAR2 179/4885SMN1; SMN2 3536/4885ALDH1A1 2074/4885 |
| US-20040054186-A1 | Cyclic protein tyrosine kinase inhibitors | LCK, ABL1, BTK | HCAR2 3940/4885SMN1; SMN2 3827/4885ALDH1A1 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.